JOHNSON AND JOHNSONNipocalimab Shows Stronger Phase 2 Signal in Autoantibody-High Sjögren’s DiseaseNipocalimab is attracting attention at EULAR 2026 as a potential new option for patients with Sjögren...

Takeda (NYSE:TAK) reported Phase 3 results showing once-daily oral zasocitinib (TAK-279) produced rapid, durable skin clearance in moderate-to-severe plaque psoriasis. At week 16, sPGA 0/1 rates were 71.4% and 69.2% versus placebo (10.7% and 12.6%) and apremilast (32.1% and 29.7%).PASI90 rates reached 61.3% and 51.9% at week 16; PASI100 reached 33.4% and 25.2%. Responses increased through week 24, and >90% of responders at week 40 maintained response at week 60. Safety was consistent with Phase 2b; no new safety signals. Takeda plans NDA submissions beginning fiscal 2026.

Sustained complete skin clearance over five years: In a subset of 153 patients from the second extension of BE BRIGHT, 67.7% of patients with moderate-to-severe plaque psoriasis (PSO) treated with BIMZELX® (bimekizumab-bkzx) achieved PASI100+ at five…